As of November 6, 2026, Eikon Therapeutics, Inc. is a publicly traded company (Nasdaq: EIKN). The largest holder reporting an active stake on Schedule 13D is The Column Group IV GP, LP, at 11.6%. No bankruptcy or receivership appears in its SEC Form 8-K filings (Schedule 13D, February 12, 2026).
Is this your company?
About to sign with, pay or invest in Eikon Therapeutics, Inc.? See the free Snapshot first.
Free to see. No signup.
Is Eikon Therapeutics, Inc. a real, registered company?
- Eikon Therapeutics, Inc. files with the SEC under CIK 1861123 (its SEC filings).
- Its shares are listed under the ticker EIKN on Nasdaq (SEC company record).
- Incorporated in Delaware; business address in Millbrae, California, as its SEC filings state.
- Court and bankruptcy records: see Before you sign or pay below.
Before you sign or pay
- Court and bankruptcy: No federal court case or bankruptcy filing found under Eikon Therapeutics, Inc. in our court records and SEC 8-K records (as of 2026-11-06).
- Ownership: 5%+ holders are reported on Schedule 13D or 13G; the latest names Fidelity (FMR) (filed 2026-10-07).
Who are Eikon Therapeutics, Inc.'s owners and officers?
Eikon Therapeutics, Inc.: incorporated in Delaware; business address in Millbrae, California; industry Biological Products, (No Diagnostic Substances) (Schedule 13G/A, 2026-10-07).
Officers and directors, each with the role and the filing that names them:
- : Executive Officer, Director (Form D, 2025-02-28)
- : Director (Form D, 2025-02-28)
- : Director (Form D, 2025-02-28)
- : Director (Form D, 2025-02-28)
- : Director (Form D, 2025-02-28)
- : Director (Form D, 2025-02-28)
- : Director (Form D, 2025-02-28)
- : Director (Form D, 2025-02-28)
| Report | Holder | Share |
|---|---|---|
| Schedule 13G/A, 2026-10-07 | Fmr LLC | 10.2% |
| Schedule 13G/A, 2026-10-02 | Abu Dhabi Investment Authority | 2.1% |
| Schedule 13G/A, 2026-08-06 | Fmr LLC | 9.2% |
| Schedule 13G, 2026-05-15 | Innovation Endeavors Iii LP | 5% |
| Schedule 13G, 2026-05-13 | Perlmutter Roger M | 5.2% |
| Schedule 13G, 2026-05-06 | Fmr LLC | 7.1% |
| Schedule 13G, 2026-04-29 | Blackrock Portfolio Management LLC | 5.5% |
| Schedule 13G, 2026-02-18 | Abu Dhabi Investment Authority | 5.2% |
| Schedule 13D, 2026-02-12 | The Column Group Iv Gp, LP | 11.6% |
| Schedule 13G, 2026-02-11 | James B. Tananbaum | 7.7% |
Questions about who owns Eikon Therapeutics, Inc.
Who owns Eikon Therapeutics, Inc.?
On this page, 6 holders' latest ownership filings report 5% or more of Eikon Therapeutics, Inc.: The Column Group Iv Gp, LP (11.6%, Schedule 13D, filed 2026-02-12), Fmr LLC (10.2%, Schedule 13G/A, filed 2026-10-07), James B. Tananbaum (7.7%, Schedule 13G, filed 2026-02-11), Blackrock Portfolio Management LLC (5.5%, Schedule 13G, filed 2026-04-29) and Perlmutter Roger M (5.2%, Schedule 13G, filed 2026-05-13); 1 more is listed above.
Who are the largest shareholders of Eikon Therapeutics, Inc.?
By the share each holder's latest filing reports, the largest holders of Eikon Therapeutics, Inc. on this page are The Column Group Iv Gp, LP (11.6%), Fmr LLC (10.2%) and James B. Tananbaum (7.7%).
When did The Column Group Iv Gp, LP buy into Eikon Therapeutics, Inc.?
The filings give report dates, not purchase dates. The earliest filing from The Column Group Iv Gp, LP on this page is the Schedule 13D, filed 2026-02-12, reporting 11.6%.
Is this an audit or a full list?
Neither. The ownership list on this page covers only Schedule 13D and 13G filings, which holders make once they own 5% or more of a class of shares (an amendment can report a stake that has since fallen below 5%); 10 such filings are shown here. It is not an audit and not a full cap table: holders who never reached 5% are not listed, and a stake can change after its latest filing.
Want the whole picture on Eikon Therapeutics, Inc.?
Example from a real report (our sample on Target): “Target eliminated approximately 1,800 corporate positions, with around 1,000 employees receiving layoff notices and the remainder accounted for by eliminating open roles.” Source: NBC News
A Full Report on Eikon Therapeutics, Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on Eikon Therapeutics, Inc. covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
17 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Which insiders own Eikon Therapeutics, Inc. shares?
Directors, officers and holders of 10% or more report their shares on Forms 3, 4 and 5. Each line is the latest such report, largest holding first.
- Column Group Opportunity III, LP, a 10% owner: 5,869,343 shares (10.8% of shares outstanding), held indirectly through By The Column Group IV, LP and 1 other, on a joint filing (Form 4, 2026-09-08).
- Column Group IV-A, LP, a 10% owner: 5,869,343 shares (10.8% of shares outstanding), held indirectly through By The Column Group IV, LP and 1 other, on a joint filing (Form 4, 2026-09-08).
- Column Group IV GP, LP, a 10% owner: 5,869,343 shares (10.8% of shares outstanding), held indirectly through By The Column Group IV, LP and 1 other, on a joint filing (Form 4, 2026-09-08).
- , a 10% owner: 5,869,343 shares (10.8% of shares outstanding), held indirectly through By The Column Group IV, LP and 1 other, on a joint filing (Form 4, 2026-09-08).
- TCG Opportunity III GP, LLC, a 10% owner: 5,869,343 shares (10.8% of shares outstanding), held indirectly through By The Column Group IV, LP and 1 other, on a joint filing (Form 4, 2026-09-08).
Shares outstanding: 54,165,030 as of 2026-08-03, from the company's latest SEC cover page.
How much has Eikon Therapeutics, Inc. raised?
| Filed | Sold | Offered |
|---|---|---|
| Form D, 2025-02-28 | $350.70M | $400M |
| Form D, 2023-06-01 | $140.76M | $535M |
Latest IPO step: Eikon Therapeutics, Inc. filed its final IPO prospectus, ticker EIKN (424B4, 2026-02-05).
IPO filings: 424B4, 2026-02-05, S-1/A, 2026-01-28, S-1, 2026-01-09; ticker EIKN on Nasdaq Global Select Market.
Keep reading
More on Eikon Therapeutics, Inc. and the records around it.
Eikon Therapeutics, Inc. elsewhere on the record
- 5%+ stake filings Oct 2026
- IPO filing Feb 2026
Companies that share a holder
- Foresite Capital Fund IV, L.P. also filed stake reports on 2 other companies: Lyell Immunopharma, Inc. (Aug 2026), Maze Therapeutics, Inc. (Nov 2025)
- Abu Dhabi Investment Authority also filed stake reports on 7 other companies: Jersey Mike's Subs Inc. (Oct 2026), AGL Private Credit Income Fund (Sep 2026), ReNew Energy Global plc (Aug 2026)
- BlackRock Portfolio Management LLC also filed stake reports on 118 other companies: AMERISAFE INC (Nov 2026), BlackRock ETF Trust (Nov 2026), iShares J.P. Morgan EM Local Currency Bond ETF (Nov 2026)
Related pages
Filings, cases and notices link to their records. A not-found line names the records searched; it is not proof of absence.
Not for employment, credit, insurance or tenancy decisions.
Cite this page
https://mentionfox.com/who-owns/eikon-therapeutics